| Literature DB >> 14552754 |
Yasutsugu Ueda1, John D Matiskella, Jerzy Golik, Timothy P Connolly, Thomas W Hudyma, Srini Venkatesh, Mandar Dali, Shin-Hong Kang, Nancy Barbour, Ravi Tejwani, Sailesh Varia, Jay Knipe, Ming Zheng, Marina Mathew, Kathy Mosure, Junius Clark, Lucinda Lamb, Ivette Medin, Qi Gao, Stella Huang, Chung-Pin Chen, Joanne J Bronson.
Abstract
Synthesis of phosphonooxymethyl derivatives of ravuconazole, 2 (BMS-379224) and 3 (BMS-315801) and their biological evaluation as potential water-soluble prodrugs of ravuconazole are described. The phosphonooxymethyl ether analogue 2 (BMS-379224) and N-phosphonooxymethyl triazolium salt 3 (BMS-315801) were both prepared from ravuconazole (1) and bis-tert-butyl chloromethylphosphate, but under two different conditions. Both derivatives were highly soluble in water and converted to the parent in alkaline phosphatase, and also in vivo (rat). However, BMS-315801 was found to be less stable than BMS-379224 in water at neutral pH. BMS-379224 (2) has proved to be one of the most promising prodrugs of ravuconazole that we tested, and it is currently in clinical evaluation as an intravenous formulation of the broad spectrum antifungal azole, ravuconazole.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14552754 DOI: 10.1016/j.bmcl.2003.08.029
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823